GoodRx (NASDAQ:GDRX) Shares Up 5.9% - What's Next?

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report)'s stock price rose 5.9% on Thursday . The company traded as high as $4.24 and last traded at $4.25. Approximately 518,995 shares changed hands during trading, a decline of 62% from the average daily volume of 1,371,963 shares. The stock had previously closed at $4.01.

Analysts Set New Price Targets

GDRX has been the subject of a number of analyst reports. UBS Group cut their price objective on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a research report on Tuesday, May 13th. The Goldman Sachs Group decreased their target price on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. Truist Financial cut their price target on shares of GoodRx from $6.50 to $5.50 and set a "hold" rating on the stock in a report on Thursday, April 10th. Finally, Wells Fargo & Company cut their price target on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating on the stock in a report on Tuesday, April 29th. Five equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $6.55.

GoodRx Trading Down 2.0%

The stock has a 50-day simple moving average of $4.26 and a two-hundred day simple moving average of $4.54. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. The firm has a market cap of $1.48 billion, a PE ratio of -138.50, a price-to-earnings-growth ratio of 2.46 and a beta of 1.16.

GoodRx (NASDAQ:GDRX - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.04 by $0.05. GoodRx had a negative net margin of 2.05% and a positive return on equity of 5.35%. The firm had revenue of $202.97 million during the quarter, compared to analyst estimates of $202.25 million. During the same quarter in the prior year, the firm earned $0.08 EPS. The business's revenue for the quarter was up 2.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that GoodRx Holdings, Inc. will post 0.13 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. National Bank of Canada FI grew its stake in shares of GoodRx by 34.9% during the 4th quarter. National Bank of Canada FI now owns 8,308 shares of the company's stock valued at $39,000 after acquiring an additional 2,151 shares during the period. Citizens Financial Group Inc. RI bought a new position in GoodRx in the 1st quarter worth approximately $44,000. RPO LLC bought a new position in GoodRx in the 4th quarter worth approximately $52,000. Jump Financial LLC bought a new position in GoodRx in the 1st quarter worth approximately $49,000. Finally, Versor Investments LP bought a new position in GoodRx in the 4th quarter worth approximately $54,000. 63.77% of the stock is currently owned by institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.